Pulse Biosciences (PLSE)
Develops nPulse systems for soft-tissue and atrial-fibrillation ablation.
Something off on this page? Send us feedback.
Builds nanosecond pulsed-field ablation systems for soft-tissue procedures and atrial-fibrillation programs. The business is still early commercially, with one reportable R&D-focused segment and progress tied to clinical execution, FDA pathways, and limited market release.
Uses Nano-pulse Stimulation, referred to as nanosecond pulsed-field ablation when ablating cellular tissue, through the nPulse System platform. Current programs center on the nPulse Vybrance Percutaneous Electrode System for soft-tissue ablation, the nPulse Cardiac Surgical System, and the nPulse 360 Cardiac Catheter for atrial fibrillation.
Commercial activity remains concentrated in the United States after an earlier dermatology rollout reached Canada and limited European markets. The current posture is early, with Vybrance in limited market release and cardiac programs advancing through pivotal-study paths.
Execution depends on clinical enrollment, FDA IDE and PMA or clearance pathways, and competition from established ablation-device makers. Control is concentrated with Robert W. Duggan, while Paul A. LaViolette leads the company as CEO and co-chairman.
Company facts
Categories
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 17, 2026 | Needham | Initiate | Buy | $58 | |
| Aug 10, 2026 | Mizuho Securities | Target | $30 | $45 | |
| Aug 10, 2026 | Canaccord Genuity | Reiterate | Buy | $32 | $43 |
| Jul 28, 2026 | Oppenheimer | Reiterate | Outperform | $30 | $35 |
| Jun 4, 2026 | Canaccord Genuity | Target | $32 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $101.6M · Total debt $6.8M · Total assets $115.6M · Shareholders' equity $99.5M
- Revenue
- $434.0K
- Operating income
- −$25.3M
- Net income
- −$24.7M
No dividends on record.
| Institutions98 holders · as of Mar 31, 2026 | 10.89% | 7.77M shares | |
| Insiders8 holders · as of Sep 2, 2026 | 71.10% | 50.71M shares | |
| Otherremainder | 18.01% | 12.84M shares |
71.32M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Robert W. DugganInsiderdirector, 10 percent owner | 69.33% | 49.45M | Form 4filed May 15, 2026 ↗ |
BlackRock, Inc.Institution | 1.88% | 1.34M | 13Fas of Mar 31, 2026 |
Bank of America Corp /DE/Institution | 1.21% | 866,061 | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 1.14% | 815,852 | 13Fas of Mar 31, 2026 |
Portolan Capital Management, LLCInstitution | 1.03% | 733,372 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 1, 2026 | Liane Rae Teplitsky | officer: Chief Operating Officer | +1,001 | $49.95 |
| Aug 31, 2026 | Liane Rae Teplitsky | officer: Chief Operating Officer | +1,024 | $48.80 |
| Aug 28, 2026 | Liane Rae Teplitsky | officer: Chief Operating Officer | +1,034 | $48.35 |
| Aug 26, 2026 | Liane Rae Teplitsky | officer: Chief Operating Officer | +1,036 | $48.24 |
| May 11, 2026 | Robert W. Duggan | director, 10 percent owner: | +660,233 | $19.69 |
- Boston Scientific
PFA platform incumbent in AF catheter ablation
- Medtronic
Large-scale AF ablation rival with PulseSelect PFA
- Johnson & Johnson
Biosense Webster PFA and CARTO workflow incumbent
- Abbott
AF PFA and EnSite mapping competitor
- AtriCure
Specialist in surgical AF ablation and hybrid therapy
- AngioDynamics
Soft-tissue electroporation ablation peer
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Pulse Biosciences | $52.70 | +1.17% | $3.65B | — | — | 3,076.8 | — |
| Boston Scientific | $48.42 | +0.09% | $71.90B | 19.7 | 14.6 | 3.4 | +7.5% |
| Medtronic | $92.40 | +0.22% | $118.00B | 22.7 | 15.3 | 3.1 | +13.7% |
| Johnson & Johnson | $274.78 | −0.17% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| Abbott | $110.50 | +0.04% | $191.19B | 35.5 | 19.0 | 4.1 | +13.0% |
| AtriCure | $52.59 | −0.06% | $2.68B | 247.8 | 351.4 | 4.7 | +12.8% |
| AngioDynamics | $15.63 | −1.45% | $645.6M | — | — | 2.0 | +8.1% |
| Median | 31.9 | 19.0 | 3.8 | +10.4% |